Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion

R Klein; D Gewaily; J Reshak; CRVOS Group; SSR Group; Q Mohamed; PA Campochiaro; DM Brown; JA Haller; Allergan; K Abel; LS Matza; B Kinge; NICE; LS Lasdon; A Ades; T Trikalinos; S Dias; HC Bucher; DJ Lunn; DM Caldwell; G Lu; NJ Welton; MJ Sweeting; A Sutton; RM Turner

doi:10.1186/1471-2288-14-140

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion

By R Klein, D Gewaily, J Reshak, CRVOS Group, SSR Group, Q Mohamed, PA Campochiaro, DM Brown, JA Haller, Allergan, K Abel, LS Matza, B Kinge, NICE, LS Lasdon, A Ades, T Trikalinos, S Dias, HC Bucher, DJ Lunn, DM Caldwell, G Lu, NJ Welton, MJ Sweeting, A Sutton and RM Turner

Publisher: 'Springer Science and Business Media LLC'

DOI identifier: 10.1186/1471-2288-14-140

OAI identifier:

Provided by: MUCC (Crossref)

Sorry, our data provider has not provided any external links therefore we are unable to provide a link to the full text.

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion

Suggested articles